Bromelain as an anti-inflammatory and anti-cancer compound
Inflammation is a complicated problem for today’s human beings. Large numbers of people have been diagnosed with arthritis along with inflammation. This is beside the others that suffer inflammation caused by an injury. There are alternatives that can be considered as temporary or permanent treatments of chronic inflammatory diseases. Plants, as well as other biological resources, are most welcomed to the therapeutic area. Using the plants’ compounds with high potential as novel techniques are today’s bio-pharmacologist concern. Bromelain has been more attractive due to its characteristics. This review is an overview of anti-inflammatory and anti-cancer effect of bromelain as a confident treatment for all inflammatory disease.
2. Bhattacharyya, B. K. (2008). Bromelain: an overview. Natural product radiance, 7(4), 359-363.
3. Yoshioka, S., Izutsu, K.-i., Aso, Y., & Takeda, Y. (2001). Inactivation kinetics of enzyme pharmaceuticals in aqueous solution. Pharmaceutical research, 8(4), 480-484.
4. Napper, A., Bennett, S., Borowski, M., Holdridge, M., Leonard, M., Rogers, E., et al. (2004). Purification and characterization of multiple forms of the pineapple-stem-derived cysteine proteinases ananain and comosain. Biochemical Journal, 301, 727-735.
5. Maurer, H. (2001). Bromelain: biochemistry, pharmacology, and medical use. Cellular and Molecular Life Sciences CMLS, 58(9), 1234-1245.
6. Gupta, P., & Saleemuddin, M. (2006). Bioaffinity based oriented immobilization of stem bromelain. Biotechnology Letters, 28(12), 917-922.
7. Mattos, P. E. O. (2005). Clinical Validation of Supplementation for Athletes Bromelain. UNIFESP.
8. Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008). Cancer-related inflammation. Nature, 454 (7203), 436-444.
9. Ferris, R. L., & Grandis, J. R. (2007). NF-κB gene signatures and p53 mutations in head and neck squamous cell carcinoma. Clinical Cancer Research, 13(19), 5663-5664.
10. Chen, F., Beezhold, K., & Castranova, V. (2008). Tumor-Promoting or Tumor Suppressing of NF-κ B, a Matter of Cell Context Dependency. International reviews of immunology, 27(4), 183-204.
11. Hussain, S. P., & Harris, C. C. (2007). Inflammation and cancer: an ancient link with novel potentials. International journal of cancer, 121(11), 2373-2380.
12. Wang, X., & Quinn, P. J. (2010). Lipopolysaccharide: Biosynthetic pathway and structure modification. Progress in lipid research, 49(2), 97-107.
13. Kalra, N., Bhui, K., Roy, P., Srivastava, S., George, J., Prasad, S., et al. (2008). Regulation of p53, nuclear factor κB and cyclooxygenase-2 expression by bromelain through targeting mitogen-activated protein kinase pathway in mouse skin. Toxicology and applied pharmacology, 226(1), 30-37.
14. Bhui, K., Prasad, S., George, J., & Shukla, Y. (2009). Bromelain inhibits COX-2 expression by blocking the activation of MAPK regulated NF-kappa B against skin tumor-initiation triggering mitochondrial death pathway. Cancer letters, 282(2), 167-176.
15. Huang, J.-R., Wu, C.-C., Hou, R. C.-W., & Jeng, K.-C. (2008). Bromelain inhibits lipopolysaccharide induced cytokine production in human THP-1 monocytes via the removal of CD14. Immunological investigations, 37(4), 263-277.
16. Hou, R. C.-W., Chen, Y.-S., Huang, J.-R., & Jeng, K.-C. G. (2006). Cross-linked bromelain inhibits lipopolysaccharide-induced cytokine production involving cellular signaling suppression in rats. Journal of agricultural and food chemistry, 54(6), 2193-2198.
17. Chobotova, K., Vernallis, A. B., & Majid, F. A. A. (2010). Bromelain’s activity and potential as an anti-cancer agent: current evidence and perspectives. Cancer letters, 290(2), 148-156.
18. Shiew, P. S., Fang, Y. L. & Majid, F. A. A. (2010). In vitro study of bromelain activity inartificial stomach juice and blood. Paper presented at the 3rd International Conference on Biotechnology for the Wellness Industry, PWTC Kuala Lumpur.
19. Engwerda, C. R., Andrew, D., Murphy, M., & Mynott, T. L. (2002). Bromelain Activates Murine Macrophages and Natural Killer Cells in vitro. Cellular Immunology, 210(1), 5-10.
20. Leipner, J., Iten, F., & Saller, R. (2001). Therapy with proteolytic enzymes in rheumatic disorders. Biodrugs, 15(12), 779-789.
21. Vogler, W. (1988). Enzymtherapie beim Weichteil-rheumatismus. Natur-Ganzheits-Med, 1, 27.
22. Klein, G., & Kullich, W. (2000). Short-term treatment of painful osteoarthritis of the knee with oral enzymes: a randomised, double-blind study versus Diclofenac. Clinical Drug Investigation, 19(1), 15-23.
23. Kane, S., & Goldberg, M. J. (2000). Use of bromelain for mild ulcerative colitis. Annals of internal medicine, 132(8), 680-680.
24. Castillo, B., Solá, R. J., Ferrer, A., Barletta, G., & Griebenow, K. (2008). Effect of PEG modification on subtilisin Carlsberg activity, enantioselectivity, and structural dynamics in 1, 4‐dioxane. Biotechnology and bioengineering, 99(1), 9-17.
25. Hale, L. P., Greer, P. K., & Sempowski, G. D. (2002). Bromelain treatment alters leukocyte expression of cell surface molecules involved in cellular adhesion and activation. Clinical Immunology, 104(2), 183-190.
26. Rovenska, E., Svik, K., Stancikova, M., & Rov-enský, J. (2000). Inhibitory effect of enzyme therapy and combination therapy with cyclosporin A on collagen-induced arthritis. Clinical and experimental rheumatology, 19(3), 303-309.
27. Thornhill, S. M., & Kelly, A.-M. (2000). Natural treatment of perennial allergic rhinitis. Alternative Medicine Review, 5(5), 448-454.
28. Brown, A. C. (2000). Lupus erythematosus and nutrition: a review of the literature. Journal of Renal Nutrition, 10(4), 170-183.
29. Wittenborg, A., Bock, P. R., Hanisch, J., Saller, R., & Schneider, B. (2000). Comparative epidemiological study in patients with rheumatic diseases illustrated in an example of a treatment with non-steroidal anti-inflammatory drugs versus an oral enzyme combination. Arzneimittel Forschung, 50(8), 728-738.
30. Lotti, T., Mirone, V., Imbimbo, C., Corrado, F., Corrado, G., Garofalo, F., et al. (2003). Controlled clinical studies of nimesulide in the treatment of urogenital inflammation. Drugs, 46(1), 144-146.